Lived Experiences of Buprenorphine

As Scotland continues its implementation of the Medication Assisted Treatment (MAT) standards, the use of long-acting injectable buprenorphine (LAIB) has grown steadily, with 23% of people in MAT prescribed it in 2024 (Public Health Scotland, 2025). Despite this, limited evidence exists on how LAIB is experienced by service users and frontline staff.

SDF completed an evaluation of lived experiences of receiving and providing LAIB, to better understand what supports and what hinders provision and how LAIB impacts individuals.